Etretinate

In this article studies about coexistence of oligoclonal and polyclonal HTLV -1-pos. T cells with presentation of acute-type adult T-cell leukemia-lymphoma successfully treated by UV B phototherapy and etretinate.We postulated that this case was not ATLL but rather a manifestation of the augmented population of oligoclonal HTLV-1-infected cells.Thus, we initiated strong topical corticosteroid ointment, etretinate 10 mg daily and narrowband UV B (UVB) on the whole body (five times per wk).After 3 wk, cutaneous lesions had completely resolved, serum sIL-2R and LDH levels normalized and flower cells were no longer present.This case highlights the importance of thorough clonality assessment in ambiguous clin. scenarios, offering valuable guidance for managing similar cases.

Palmoplantar pustular psoriasis (PPPP), or palmoplantar pustulosis (PPP), is a type of psoriasis that affects the skin on the palms and soles. It is characterised by dermatosis and small sterile pustules and is considered a significant burden on patients' quality of life, as there is currently no gold standard treatment or cure. This network meta‐analysis (NMA) compares the efficacy and safety of biologic and non‐biologic medications for PPPP and PPP. Medline, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched. The efficacy and safety of all medications were assessed through a frequentist NMA using a random‐effects model. Treatments were ranked using the net rank function, yielding P scores. Fourteen RCTs with 1056 participants were included. Guselkumab 100 mg was the most effective for improving PPPGA scores (p = 0.72, RR = 1.31, CI: 0.31–5.57). Guselkumab 100 mg was ranked the highest for achieving PPPASI‐75 (RR = 5.4, CI: 1.26–23.2, p = 0.023). Oral cyclosporine 1 mg/kg/day was ranked the highest for PPPASI‐50 (RR = 2.10, CI: 0.65–6.82). Etretinate 1 mg/kg/day had the highest rate of adverse events (RR = 1.78, CI: 0.92–3.44). Secukinumab 300 mg was associated with the highest rate of serious adverse events (RR = 1.58, CI: 0.21–12.02). Based on the P‐scores from our NMA, guselkumab 100 mg was the most effective for PPPGA improvement, guselkumab 100 mg for PPPASI‐75, oral cyclosporine 1 mg/kg/day for PPPASI‐50, etretinate 1 mg/kg/day had the most adverse events, and secukinumab 300 mg was associated with the highest rate of serious adverse events.

PROSPERO registration number: CRD42023460842